Ascendis Pharma A/S
ASND
103 hedge funds and large institutions have $2.51B invested in Ascendis Pharma A/S in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 40 reducing their positions, and 10 closing their positions.
95% more call options, than puts
Call options by funds: $58.1M | Put options by funds: $29.8M
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
7% more funds holding
Funds holding: 96 → 103 (+7)
0% more funds holding in top 10
Funds holding in top 10: 13 → 13 (0)
0.64% less ownership
Funds ownership: 96.05% → 95.41% (-0.64%)
12% less capital invested
Capital invested by funds: $2.85B → $2.51B (-$338M)
25% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.8M |
| 2 |
DM
Deerfield Management
New York
|
+$11.6M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.66M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$8.5M |
| 5 |
Bank of New York Mellon
New York
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$61.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$25.6M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.32M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$6.28M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.07M |
ASND Hedge Fund Activity: Q4 2018 in Review
103 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2018, worth a combined $2.51B — down 12% from $2.85B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ASND positions and 10 closed out — a net gain of 8 holders — while 30 added to existing stakes and 40 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $45.8M. The largest seller was Sofinnova Investments, cutting an estimated $61.6M.
- 103 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2018, up from 96 in Q3 2018.
- Funds reported $2.51B of Ascendis Pharma A/S stock for Q4 2018, down 12% quarter-over-quarter.
- 18 funds opened new Ascendis Pharma A/S positions in Q4 2018 and 10 closed out, a net change of +8 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2018 was T. Rowe Price Associates, an estimated $45.8M added.
- The largest Ascendis Pharma A/S seller in Q4 2018 was Sofinnova Investments, an estimated $61.6M sold.
Based on aggregated 13F filings for Q4 2018.